Dry powder formulation comprising a phosphodiesterase inhibitor.

Abstract

The invention relates to an inhalable dry powder formulation, comprising: micronized particles of the (-) enantiomer of active ingredient 3cyclopropylmethoxy-4methanesulfonylamino-benzoic acid 1-(3cyclopropylmethoxy-4-difluoromethoxy-phenyl)2-(3 ,5-dichloro- 1 -oxy-pyridin-4-yl)-ethyl ester; and particles of a carrier comprising a mixture of coarse particles comprised of alpha-lactose monohydrate having a mass diameter of 150 to 400 microns, finely divided particles comprised of alpha-lactose monohydrate having a mass median diameter (MMD) equal to or less than 10 microns, and magnesium stearate.